ClinicalTrials.Veeva

Menu

HUMIRA® Long-term Treatment in Patients With Non-infectious Intermediate-, Posterior-, or Pan-uveitis

AbbVie logo

AbbVie

Status

Completed

Conditions

Uveitis

Study type

Observational

Funder types

Industry

Identifiers

NCT02916017
P15-665

Details and patient eligibility

About

This study evaluates the long- term safety and effectiveness of adalimumab in participants with non-infectious intermediate-, posterior-, or pan-uveitis in daily practice in Japan.

Enrollment

259 patients

Sex

All

Ages

Under 100 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Participants receiving adalimumab for the treatment of Non-infectious Intermediate-, Posterior-, or Pan-uveitis

Exclusion criteria

  • Participants previously treated with adalimumab

Trial design

259 participants in 1 patient group

Participants receiving adalimumab
Description:
Participants receiving adalimumab for the treatment of Non-infectious Intermediate-, Posterior-, or Pan-uveitis

Trial contacts and locations

39

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems